Health
Eli Lilly Advances Obesity Drug Development
Eli Lilly is set to file for approval of its next-generation obesity drug, retatrutide, in 2027 after positive results from five late-stage trials. However, new data raises questions about the drug's heart benefits.
Coverage timeline — 2 articles
STAT News
On secondary endpoints that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.
2026-07-23 10:45 UTC
CNBC
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
2026-07-23 10:45 UTC